These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 2544125)

  • 1. The ex vivo correlate of the antithrombotic action of heparin.
    Hemker HC; Béguin S; Pieters J; Lindhout T
    Ann N Y Acad Sci; 1989; 556():146-57. PubMed ID: 2544125
    [No Abstract]   [Full Text] [Related]  

  • 2. Mode of action of heparin and related drugs.
    Hemker HC; Beguin S
    Semin Thromb Hemost; 1991; 17 Suppl 1():29-34. PubMed ID: 1648791
    [No Abstract]   [Full Text] [Related]  

  • 3. Heparin and low-molecular-weight heparin.
    Gray E; Mulloy B; Barrowcliffe TW
    Thromb Haemost; 2008 May; 99(5):807-18. PubMed ID: 18449410
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The limited importance of factor Xa inhibition to the anticoagulant property of heparin in thromboplastin-activated plasma.
    Pieters J; Lindhout T
    Blood; 1988 Dec; 72(6):2048-52. PubMed ID: 3196877
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between ex vivo anti-proteinase (factor Xa and thrombin) assays and in vivo anticoagulant effect of very low molecular weight heparin, CY222.
    Tew CJ; Lane DA; Thompson E; Ireland H; Curtis JR
    Br J Haematol; 1988 Nov; 70(3):335-40. PubMed ID: 2849981
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heparin monitoring and thrombosis.
    Glynn MF
    Am J Clin Pathol; 1979 Apr; 71(4):397-400. PubMed ID: 443197
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low molecular weight heparins: antithrombotic and haemorrhagic effects and standardization.
    Barrowcliffe TW; Thomas DP
    Acta Chir Scand Suppl; 1988; 543():57-64. PubMed ID: 2847459
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heparin and low molecular weight heparin: is anti-factor Xa activity important?
    Lane DA; Ryan K
    J Lab Clin Med; 1989 Oct; 114(4):331-3. PubMed ID: 2551984
    [No Abstract]   [Full Text] [Related]  

  • 9. Inhibition of thrombin-catalyzed reactions in blood coagulation and platelet activation by heparin fractions in the absence of antithrombin III.
    Baruch D; Lindhout T; Wagenvoord R; Hemker HC
    Haemostasis; 1986; 16(2):71-81. PubMed ID: 3086193
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LMW heparin: relationship between antithrombotic and anticoagulant effects.
    Barrowcliffe TW
    Adv Exp Med Biol; 1992; 313():205-20. PubMed ID: 1332437
    [No Abstract]   [Full Text] [Related]  

  • 11. Molecular weight of heparin versus biologic activity. Some additional considerations.
    Losito R; Losito C
    Semin Thromb Hemost; 1985 Jan; 11(1):29-33. PubMed ID: 2579437
    [No Abstract]   [Full Text] [Related]  

  • 12. Relative efficacy of heparin and related glycosaminoglycans as antithrombotic drugs.
    Thomas DP; Merton RE; Barrowcliffe TW
    Ann N Y Acad Sci; 1989; 556():313-22. PubMed ID: 2735662
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Significance of thrombin-receptors of thrombocytes for the interaction of heparins and low-molecular-weight heparin in human whole blood clotting.
    Harenberg J; Schuler M; Zimmermann R; Heptner W
    Haemostasis; 1988; 18 Suppl 3():20-2. PubMed ID: 2840370
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Time-course of anti-Xa effects of calcium heparin and low-molecular-weight heparin given s.c.: insights for thrombosis prevention.
    Romeo G; Salanitri G; Catania G
    Drugs Exp Clin Res; 1988; 14(6):423-7. PubMed ID: 2850903
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antithrombotic effects of heparin oligosaccharides.
    Mattsson C; Palm M; Söderberg K; Holmer E
    Ann N Y Acad Sci; 1989; 556():323-32. PubMed ID: 2735663
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of unfractionated and fractionated heparin on platelet function.
    Heinrich D; Görg T; Schulz M
    Haemostasis; 1988; 18 Suppl 3():48-54. PubMed ID: 2840374
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hirudin versus heparin and low-molecular-weight heparin: and the winner is..
    Hull RD; Pineo GF; Raskob GE
    J Lab Clin Med; 1998 Sep; 132(3):171-4. PubMed ID: 9735921
    [No Abstract]   [Full Text] [Related]  

  • 18. Guide to anticoagulant therapy: Heparin : a statement for healthcare professionals from the American Heart Association.
    Hirsh J; Anand SS; Halperin JL; Fuster V;
    Circulation; 2001 Jun; 103(24):2994-3018. PubMed ID: 11413093
    [No Abstract]   [Full Text] [Related]  

  • 19. Comparative study on a new one-stage clotting assay for heparin and its low molecular weight derivatives.
    Harenberg J; Giese C; Knödler A; Zimmermann R
    Haemostasis; 1989; 19(1):13-20. PubMed ID: 2537786
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is tissue factor pathway inhibitor involved in the antithrombotic effect of heparins? Biochemical considerations.
    Ostergaard P; Nordfang O; Petersen LC; Valentin S; Kristensen H
    Haemostasis; 1993 Mar; 23 Suppl 1():107-11. PubMed ID: 8388348
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.